Vigil Neuroscience
Developing drugs for neurodegenerative diseases.
Market cap
$371m
Enterprise value
$296m
Share price
$7.95 VIGL
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | $470m | Acquisition | |
| Total Funding | 000k | ||
Northpond Ventures(exited)
Atlas Venture(exited)
Hatteras Venture Partners(exited)
Alexandria Venture Investments(exited)
Vida Ventures(exited)
Surveyor Capital(exited)
Cormorant Asset Management(exited)
Invus(exited)
OrbiMed(exited)
Rock Springs Capital(exited)
Deep Track Capital(exited)
Pivotal Life Sciences(exited)
Lightstone Ventures(exited)
Logos Capital(exited)
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | - | 2484 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.